This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Varian Medical Systems Appoints Deepak "Dee" Khuntia M.D. Vice President Of Medical Affairs

PALO ALTO, Calif., March 28, 2013 /PRNewswire/ -- Varian Medical Systems (NYSE: VAR) today announced the appointment of Deepak "Dee" Khuntia, M.D., to vice president, Medical Affairs.  He will report to Kolleen Kennedy, corporate senior vice president and president of Varian's Oncology Systems business, the world's leading provider of radiotherapy technology for the treatment of cancer.  Khuntia will partner closely with Varian's Quality & Regulatory teams, providing clinical and scientific guidance in all areas of clinical risk, safety reviews, adverse experience reporting, product life cycle reviews and clinical protocol design.

"Dee brings a wealth of directly relevant experience to this important role," said Kennedy.  "He is a well-reputed thought leader in the field of oncology with a special interest in advanced radiation delivery techniques as well as medical informatics, continuing education, and healthcare policy.  With his broad experience and strong leadership skills, I am confident that he will help us maximize the clinical potential of our product development efforts and collaborative research partnerships with a strong focus on healthcare economics."

Khuntia has led multiple national and international clinical trials designed to advance the standards of care in the treatment of brain, lung, head and neck, and prostate cancer.  A widely published clinical researcher, his presentations and papers have spanned a broad range of topics including radiotherapy, radiosurgery, and imaging techniques in the treatment of cancer. Passionate about education and broad scale quality cancer care delivery, he has lectured worldwide helping to bridge the knowledge gap that exists with the recent surge of advanced radiation techniques.

Khuntia joined Varian earlier this month after serving two years as director of research and education for a large private practice in the San Francisco Bay area.  Prior to that, he practiced at the University of Wisconsin in Madison, where he served in many leadership roles, including Residency Program Director, Vice-Chair of Radiation Oncology Outreach, and Course Director for Neoplastic Diseases at the University of Wisconsin School of Medicine and Public Health. 

Khuntia holds a medical degree from the University Of Illinois College Of Medicine, and completed his radiation oncology residency at the Cleveland Clinic Foundation.

About Varian Medical SystemsVarian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes, digital detectors, and image processing workstations for X-ray imaging in medical, scientific, and industrial applications and also supplies high-energy X-ray devices for cargo screening and non-destructive testing applications.  Varian Medical Systems employs approximately 6,200 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world. For more information, visit http://www.varian.com or follow us on Twitter.

FOR INFORMATION CONTACT:

Varian Medical Systems Meryl Ginsberg, 650.424.6444 meryl.ginsberg@varian.com

SOURCE Varian Medical Systems

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,325.43 +59.44 0.34%
S&P 500 2,018.43 +7.07 0.35%
NASDAQ 4,609.1580 +15.7330 0.34%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs